Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 In
about
Vascular endothelial dysfunction and pharmacological treatmentLDL cholesterol, statins and PCSK 9 inhibitorsPCSK9 and triglyceride-rich lipoprotein metabolismNew therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugsProfile of evolocumab and its potential in the treatment of hyperlipidemiaDevelopment of proprotein convertase subtilisin/kexin type 9 inhibitors and the clinical potential of monoclonal antibodies in the management of lipid disordersPCSK9 inhibitors in the prevention of cardiovascular diseaseNew Era of Lipid-Lowering DrugsPCSK9 inhibitors - clinical applicationsA century of cholesterol and coronaries: from plaques to genes to statinsPCSK9 Inhibition With Monoclonal Antibodies: Modern Management of HypercholesterolemiaAPOM and high-density lipoprotein cholesterol are associated with lung function and per cent emphysema.Modulators of hepatic lipoprotein metabolism identified in a search for small-molecule inducers of tribbles pseudokinase 1 expressionFuture translational applications from the contemporary genomics era: a scientific statement from the American Heart AssociationTherapeutic efficacy and safety of PCSK9-monoclonal antibodies on familial hypercholesterolemia and statin-intolerant patients: A meta-analysis of 15 randomized controlled trials.Efficacy and safety of proprotein convertase subtilisin/kexin type 9 monoclonal antibody in adults with familial hypercholesterolemiaEfficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies.PCSK9 inhibitors - from discovery of a single mutation to a groundbreaking therapy of lipid disorders in one decade.Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society.Familial hypercholesterolemia: developments in diagnosis and treatmentAncestry and other genetic associations with plasma PCSK9 response to simvastatin.Proprotein convertases in high-density lipoprotein metabolism.Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial.Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs.Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9).A Mechanistic Systems Pharmacology Model for Prediction of LDL Cholesterol Lowering by PCSK9 Antagonism in Human Dyslipidemic PopulationsPCSK9 antibodies for the treatment of hypercholesterolemiaPCSK9 inhibition to reduce cardiovascular disease risk: recent findings from the biology of PCSK9.Efficiency and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibody on hypercholesterolemia: a meta-analysis of 20 randomized controlled trials.Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trialsEfficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher.New Approaches in Detection and Treatment of Familial HypercholesterolemiaElevated PCSK9 levels in untreated patients with heterozygous or homozygous familial hypercholesterolemia and the response to high-dose statin therapyPCSK9 - A New and Potent Approach to Lowering Cholesterol.Effect of monoclonal antibodies to PCSK9 on high-sensitivity C-reactive protein levels: a meta-analysis of 16 randomized controlled treatment armsPCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role.HIV and Hepatitis C-Coinfected Patients Have Lower Low-Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent "PCSK9-Lipid Paradox".Analysis of the frequency and spectrum of mutations recognised to cause familial hypercholesterolaemia in routine clinical practice in a UK specialist hospital lipid clinic.Dyslipidemia in obesity: mechanisms and potential targetsEfficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia.
P2860
Q26774561-CA9FF221-8214-42BF-9BB4-98C202E5F37AQ26782522-F7F42F43-4889-45D3-852F-4072D825D72BQ26796287-5E616A7B-CDB3-47BB-B2C8-344DB7FB73C8Q26863369-C270F145-C86C-4BF4-B1DA-CBCBC2BC0001Q27004235-6F444263-BB3A-4269-9C2E-40BD5CE0316FQ28070296-45945E57-71AB-4ACD-8CBF-C1782C7607B3Q28071452-26C44A06-DCB3-47AA-A7F3-6C2B8434A079Q28072298-1E1E6D73-12EE-4C80-A04C-45CFA5ECA40BQ28079757-6DC89F80-CE8C-4156-8B89-81513E799CAFQ28080618-D1706997-B29A-4AB9-8064-844C1CBF8B3EQ28275648-10A27280-3E72-4C43-B3B5-C37CA24BF5F6Q28387051-28652901-4A9A-4ACA-B13A-AC0EF0BA96B8Q28545029-74F6E261-42DA-46B8-B5DC-7A6CAA5C7FC8Q30359686-D445CFAA-6661-4B3F-8501-FEA636397242Q33670893-148BD04D-87D0-4AAD-B37B-F8F9D2E55D59Q33728343-137B447F-A508-4A97-8FE1-49053D22120AQ33818871-8278D7EE-793D-4442-9EE5-AD53B8B77325Q33904455-4208AED5-70CF-4DC9-97F8-DCF2E9BEC294Q34071937-5EA69200-A0A3-456D-B165-9A6864902F81Q34106665-71AE003B-CE5B-4552-B62E-8B70159B06C9Q34157965-BD7E8B69-3216-4E2B-9F13-67546DDC0949Q34256139-C778633F-9E83-4C5B-8266-115C68C5A5ABQ34375398-A05597C5-B57E-467B-8FD2-5339F206C899Q34430377-80FEBB65-254A-4479-B4C2-9F8215B1D696Q34458693-5FE7484A-E2AB-493D-98F0-15768EE1488BQ34658086-167E186B-D610-4422-AD57-8420CFE5C109Q34774969-AB3B2ECD-D9C6-4F89-B61B-45E4513B648DQ35262593-079571C1-0831-4C1D-9022-0486EBE6E56DQ35664577-3BC106FA-13E5-44F3-B3A9-C66CFF88A6C6Q35671077-7C691566-6F02-49DE-9968-D876E68E430DQ36130225-4362161E-5D50-4E79-B9A0-B5F8B1B8E3D6Q36177473-12BD07DF-8982-45C4-B39C-09A15572C5FDQ36824813-C75846BB-5477-4710-96D4-F3F322625EA2Q36921224-B2CC4905-7583-4C1F-995D-BBC40A7F9D31Q36924697-C7DD222A-33C7-4DB2-8F61-C2AE564587C8Q36930207-2059EBC4-486F-406E-8B12-B9F0A001D997Q36956654-B700E067-1D9C-4C46-A422-7A3E05578E71Q36983486-E1121CD5-D83C-4BA4-9FF2-3C1BA6086DD2Q36994072-21FB397B-5405-42B6-9BAD-533E934C1EADQ37034257-95BF3EDD-15E9-4C0C-9277-83832FF193E8
P2860
Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 In
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Low-density lipoprotein choles ...... duction of LDL-C with PCSK9 In
@en
type
label
Low-density lipoprotein choles ...... duction of LDL-C with PCSK9 In
@en
prefLabel
Low-density lipoprotein choles ...... duction of LDL-C with PCSK9 In
@en
P2093
P921
P1433
P1476
Low-density lipoprotein choles ...... duction of LDL-C with PCSK9 In
@en
P2093
Evan A Stein
Frederick Raal
Ian Bridges
Ransi Somaratne
Scott M Wasserman
P304
P356
10.1161/CIRCULATIONAHA.112.144055
P407
P577
2012-11-05T00:00:00Z